Company

InnoCare Pharma Ltd

Headquarters: Beijing, China

Employees: 531

CEO: Dr. Jisong Cui

HKEX: 9969 +0.10%

Market Cap

HK$11.97 Billion

HKD as of Jan. 1, 2025

US$1.54 Billion

Market Cap History

InnoCare Pharma Ltd market capitalization over time

Evolution of InnoCare Pharma Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of InnoCare Pharma Ltd

Detailed Description

InnoCare Pharma Limited, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It offers Orelabrutinib (ICP-022), a Bruton's tyrosine kinase for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma, and relapsed and refractory mantle cell lymphoma. ICP-022 is in Phase II studies for patients with relapsed and refractory marginal zone lymphoma, relapsed and refractory central nervous system lymphoma, and relapsed and refractory Waldenstrom's macroglobulinemia; and in a Phase I clinical trial for follicular lymphoma patients, as well as Phase I basket trial for B-cell malignancies. The company is developing Gunagratinib( ICP-192), a pan-inhibitor of fibroblast growth factor receptor (FGFR) that is in Phase I/IIa clinical trial to define its maximum tolerated dose and/or optimal biological dose, and pharmacokinetics/ pharmacodynamics in patients with solid tumors; and ICP-105, a FGFR4 inhibitor, which is in Phase I dose escalation trial for the treatment of advanced hepatocellular carcinoma. It is also developing ICP-723, a pan-inhibitor of tropomyosin-related kinase family that is in Phase I clinical trial to treat patients with neurotrophic tyrosine receptor kinase fusion-positive cancers; and ICP-332, a small-molecule inhibitor of tyrosine kinase 2 for the treatment of various T-cell mediated autoimmune disorders, such as psoriasis, inflammatory bowel disease, and systemic lupus erythematosus. The company was incorporated in 2015 and is headquartered in Beijing, China.

Financials

Last Financial Reports Date June 30, 2024
Revenue TTM HK$964.8 M
EBITDA HK$-591,442,476
Gross Profit TTM HK$830.0 M
Profit Margin -41.77%
Operating Margin -35.98%
Quarterly Revenue Growth 74.00%
Financial Reports & Statistics

Stocks & Indices

InnoCare Pharma Ltd has the following listings and related stock indices.


Stock: HKEX: 9969 wb_incandescent

Details

Headquarters:

Zhongguancun Life Science Park

Building 8 No. 8 Life Science Park Road Changping District

Beijing, 102206

China

Phone: 86 10 6660 9999

Fax: 86 10 6070 2992